Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
1(9%)
Results Posted
40%(4 trials)

Phase Distribution

Ph phase_3
2
18%
Ph not_applicable
1
9%
Ph phase_1
4
36%
Ph phase_2
1
9%
Ph phase_4
1
9%

Phase Distribution

4

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
1(11.1%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(10)

Detailed Status

Completed10
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (44.4%)
Phase 21 (11.1%)
Phase 32 (22.2%)
Phase 41 (11.1%)
N/A1 (11.1%)

Trials by Status

completed1091%
recruiting19%

Recent Activity

1 active trials
Showing 5 of 11
recruitingnot_applicable

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

NCT07184853
completedphase_1

Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers

NCT01894412
completedphase_1

Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection

NCT02799498
completedphase_3

The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease

NCT00726375
completed

Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings

NCT00708708
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07184853Not Applicable

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

Recruiting
NCT01894412Phase 1

Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers

Completed
NCT02799498Phase 1

Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection

Completed
NCT00726375Phase 3

The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease

Completed
NCT00708708

Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings

Completed
NCT01431404Phase 1

Safety and Pharmacokinetic Characteristics of HD203 Liq. in Healthy Subjects

Completed
NCT00683384

Study Evaluating the Safety of Enbrel (Etanercept)

Completed
NCT00420238Phase 4

Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis

Completed
NCT00524381Phase 3

Etanercept Treatment in the Early Course of Polymyalgia Rheumatica

Completed
NCT00091741Phase 1

Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects

Completed
NCT00006070Phase 2

Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11